Ono Enters into License Agreement with Bial
News Apr 30, 2013
BIA 9-1067 (development code) (generic name: Opicapone) in Japan, is a long acting COMT (Cathechol-O-Methyl Transferase) inhibitor originated by and currently being developed outside Japan by Bial (Porto, Portugal, CEO: António Portela) for the treatment of symptom reemergence due to levodopa “wearing-off” in Parkinson’s disease (PD).
Under the License Agreement, Ono will pay Bial an upfront fee and development and sales milestones based on the development stage and sales performance of Opicapone.
Opicapone is an adjunct therapy to levodopa preparations (levodopa/carbidopa or levodopa/benserazide) in PD patients. It is well established that levodopa preparations offer the most effective symptomatic treatment of PD. As the disease progresses, PD patients develop “wearing off” phenomenon, where the duration of the effect of levodopa is shortened. To address this “wearing off” phenomenon, adjunctive therapy to levodopa preparations is used to help maintain or boost the effects of levodopa. COMT inhibitors have been widely used to prolong the duration of levodopa effect.
The existing COMT inhibitor in Japan requires multiple administration per day due to its short duration of action and is concomitantly administered with each levodopa preparation.
Phase 3 clinical studies of Opicapone by BIAL are currently ongoing and in clinical studies so far it has demonstrated an increase in the systemic exposure to levodopa and showed a long-lasting effect on COMT inhibition from once daily dosing. Opicapone is expected to improve a dosing convenience, compared to the existing COMT inhibitor in Japan.
Ono will continue to make great efforts to offer a new drug which truly contributes to patients wellbeing and fulfills unmet medical needs.
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018